Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.57 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.57 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.57 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | FASN | P49327 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11140389 | 0.90 | ALDH1A1 (0.56) | GRIA1GRIA2GRIA3GRIA4CYP19A1 | |
| SCHEMBL30881362 | 0.81 | GRIA1 (0.60) | GRIA1GRIA2GRIA3GRIA4CYP19A1 | |
| SCHEMBL27015077 | 0.80 | F12 (0.49) | GRIA1GRIA2GRIA3GRIA4POLB | |
| SCHEMBL27885276 | 0.80 | HRH4 (0.61) | GRIA1GRIA2GRIA3GRIA4CYP19A1 | |
| SCHEMBL24207597 | 0.78 | GRIA1 (0.60) | GRIA1GRIA2GRIA3GRIA4CYP19A1 | |
| SCHEMBL14722450 | 0.78 | GRIA1 (0.60) | GRIA1GRIA2GRIA3GRIA4CYP19A1 | |
| SCHEMBL20267527 | 0.78 | GRIA1 (0.60) | GRIA1GRIA2GRIA3GRIA4CYP19A1 | |
| SCHEMBL29533215 | 0.78 | GRIA1 (0.60) | GRIA1GRIA2GRIA3GRIA4CYP19A1 | |
| SCHEMBL3598675 | 0.78 | GRIA1 (0.55) | GRIA1GRIA2GRIA3GRIA4PARP1 | |
| SCHEMBL31154578 | 0.76 | GRIA1 (0.57) | GRIA1GRIA2GRIA3GRIA4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-05 | — | — | US | claimed |
| WO-2006132947-A2 | 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-12-14 | — | — | WO | claimed |
| US-8067461-B2 | 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2006132947-A2 | 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | NQO2, NQO1, HCCS | GRIA1 4741/4885GRIA2 4802/4885GRIA3 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.